Business Context and Reporting Period
This Form 8-K was filed by Recursion Pharmaceuticals, Inc. on January 13, 2023. The report discloses a material change in executive leadership regarding the Company's legal department.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
- Departure: Louisa Daniels has ended her employment as Chief Legal Officer and General Counsel.
- Appointment: Nathan Hatfield was appointed Senior Vice President, Head of Legal, effective January 13, 2023.
- Transition: Mr. Hatfield will assume all responsibilities previously held by Ms. Daniels and will join the executive team.
Management Commentary and Background
Management thanked Ms. Daniels for her contributions, specifically noting her role in guiding the Company through its transition to a public company and building an effective legal team. Mr. Hatfield has been with the Company since early 2017, most recently serving as Senior Vice President of Legal and Associate General Counsel. Prior to joining Recursion, he was a corporate and securities attorney at Wilson Sonsini.
Key Facts for Investor Verification
- Confirm the effective date of the leadership transition (January 13, 2023).
- Verify Mr. Hatfield's tenure and prior roles within the Company to assess continuity.
- Note that this filing is a Regulation FD disclosure and is not deemed "filed" for Section 18 liability purposes under the Exchange Act.